
In this segment, the panel discusses how emerging therapies may be incorporated into treatment for patients with advanced squamous non-small cell lung cancer (NSCLC) who have experienced challenges with prior immune checkpoint inhibitors.

In this segment, the panel discusses how emerging therapies may be incorporated into treatment for patients with advanced squamous non-small cell lung cancer (NSCLC) who have experienced challenges with prior immune checkpoint inhibitors.

In this segment, the panel discusses treatment considerations for patients with advanced squamous non-small cell lung cancer (NSCLC) who have progressed following immunotherapy and platinum-based chemotherapy but do not want additional chemotherapy.

In this segment, the panel discusses the emerging safety profile of next-generation CTLA-4-directed therapy in advanced squamous non-small cell lung cancer (NSCLC) and how toxicity findings should be interpreted alongside efficacy data.

In this segment, the panel reviews additional clinical data from the initial stage of the trial evaluating next-generation CTLA-4-directed therapy in advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel examines early clinical data for a next-generation CTLA-4-directed therapy in patients with advanced squamous non-small cell lung cancer (NSCLC) whose disease has progressed following PD-L1 inhibitor and chemotherapy treatment.

In this segment, the panel explores the rationale for selectively targeting CTLA-4 within the tumor microenvironment in advanced squamous non-small cell lung cancer (NSCLC), with particular attention to intratumoral regulatory T cells (Tregs) and the potential to improve antitumor activity while limiting systemic toxicity.

In this segment, the panel discusses next-generation CTLA-4-directed therapies being engineered with the goal of improving selectivity and reducing the systemic toxicities associated with earlier CTLA-4 inhibitors in advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel discusses the importance of proactive monitoring and multidisciplinary management of immune-related toxicities in patients with advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel discusses the toxicity profile of CTLA-4-directed therapies and how experience with immune-modulating treatments has influenced their use in advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel explains the biological rationale for combining CTLA-4 and PD-1 inhibition in advanced squamous non-small cell lung cancer (NSCLC).

In this segment, the panel discusses the potential role of genomic testing and biomarker identification in advanced squamous non-small cell lung cancer (NSCLC), particularly as new therapeutic approaches emerge following immunotherapy.

In this segment, Dr. Christian Rolfo reviews emerging therapeutic approaches being investigated for patients with advanced squamous non-small cell lung cancer (NSCLC) following progression on immunotherapy.

Explore post-immunotherapy options for advanced squamous NSCLC, weighing docetaxel±ramucirumab, patient concerns, and why new trials matter.

When immunotherapy stops working in squamous NSCLC, clinicians weigh docetaxel±ramucirumab, weekly dosing, and clinical trials.

Edward S. Kim, MD, MBA, discusses the purpose and value of the Bridging the Gaps in Lung Cancer meeting.

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.

Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.

The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.

D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.

Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.

Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.

A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).

October 21st 2026

October 21st 2026

April 17th 2024

October 28th 2026

July 13th 2022